Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Willingness To Pay for HPV Vaccine Among Women Living With HIV in Nigeria

Folahanmi Akinsolu
* ,
Olunike Abodunrin
,
Ifeoluwa Adewole
ORCID logo ,
Mobolaji Olagunju
,
Aisha O Gambari
,
Dolapo Raji
,
Ifeoma Idigbe
,
Diana W Njuguna
,
Abideen Salako
,
Oliver Ezechi
ORCID logo
Version 1 : Received: 21 March 2023 / Approved: 23 March 2023 / Online: 23 March 2023 (02:45:10 CET)

A peer-reviewed article of this Preprint also exists.

Akinsolu, F.T.; Abodunrin, O.; Adewole, I.E.; Olagunju, M.; Gambari, A.O.; Raji, D.O.; Idigbe, I.E.; Njuguna, D.W.; Salako, A.; Ezechi, O.C. Willingness to Pay for HPV Vaccine among Women Living with HIV in Nigeria. Vaccines 2023, 11, 928. Akinsolu, F.T.; Abodunrin, O.; Adewole, I.E.; Olagunju, M.; Gambari, A.O.; Raji, D.O.; Idigbe, I.E.; Njuguna, D.W.; Salako, A.; Ezechi, O.C. Willingness to Pay for HPV Vaccine among Women Living with HIV in Nigeria. Vaccines 2023, 11, 928.

Abstract

Background: Human papillomavirus (HPV) is responsible for most cervical cancer cases globally, with women living with HIV at higher risk of persistent HPV infection and HPV-associated disease. The HPV vaccine is a promising solution to reducing cervical cancer rates, but its uptake among women living with HIV in Nigeria is unknown. Methods: A facility-based, cross-sectional survey was conducted with 1,371 women living with HIV to assess their knowledge of HPV, cervical cancer, and the HPV vaccine, as well as their willingness to pay for the vaccine at the HIV treatment clinic, Nigerian Institute of Medical Research, Lagos. Willingness to pay for the HPV vaccine was also assessed. Multivariable logistic regression models were developed to identify factors associated with willingness to pay for the HPV vaccine. Results: The study found that 79.1% of participants had not heard of the vaccine, and only 29.0% knew of its efficacy in preventing cervical cancer. Moreover, 68.3% of participants were unwilling to pay for the vaccine, and the average amount they were willing to pay was low. Knowledge of HPV, the HPV vaccine, cervical cancer, and income were factors associated with willingness to pay for the vaccine. Health workers were the primary source of information. Conclusion: The study found that 79.1% of participants had not heard of the vaccine, and only 29.0% knew of its efficacy in preventing cervical cancer. Moreover, 68.3% of participants were unwilling to pay for the vaccine, and the average amount they were willing to pay was low. Knowledge of HPV, the HPV vaccine, cervical cancer, and income were factors associated with willingness to pay for the vaccine. Health workers were the primary source of information.

Keywords

HPV; Cervical cancer; HPV vaccine; Women; HIV

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.